Interleukin 6, Ferritin Levels, and Glasgow Prognostic Score in Solid Cancer

Linda Rotty; Mersy Padang; Cecilia Hendratta; Harlinda Haroen; Pearla Lasut

doi:10.3889/oamjms.2022.10958

Authors

Linda Rotty Department of Internal Medicine, Division of Hematology-Oncology, Faculty of Medicine, Sam Ratulangi University, Prof. Dr. R. D. Kandou Hospital, Manado, Indonesia
Mersy Padang Department of Internal Medicine, Faculty of Medicine, Sam Ratulangi University, Prof. Dr. R. D. Kandou Hospital, Manado, Indonesia
Cecilia Hendratta Department of Internal Medicine, Division of Hematology-Oncology, Faculty of Medicine, Sam Ratulangi University, Prof. Dr. R. D. Kandou Hospital, Manado, Indonesia
Harlinda Haroen Department of Internal Medicine, Division of Hematology-Oncology, Faculty of Medicine, Sam Ratulangi University, Prof. Dr. R. D. Kandou Hospital, Manado, Indonesia
Pearla Lasut Department of Internal Medicine, Division of Hematology-Oncology, Faculty of Medicine, Sam Ratulangi University, Prof. Dr. R. D. Kandou Hospital, Manado, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.10958

Keywords:

Solid cancer, Interleukin 6, Ferritin, Glasgow Prognostic Score

Abstract

BACKGROUND: Several pro-inflammatory cytokines have been shown to regulate cancer cell growth and contribute to cancer promotion and progression. Interleukin 6 (IL-6) regulates almost all the hallmarks of cancer such as inhibition of apoptosis, proliferation, angiogenesis, and invasiveness and is also known to regulate cell metabolism. The associated increase in serum ferritin is most likely induced by the inflammatory state. In several studies, IL-6 and ferritin have a significant role in the development and clinical outcome in solid cancer and the Glasgow Prognostic Score (GPS) is widely used as a prognostic score in solid cancer. It is currently unclear whether levels of IL-6 and ferritin correlate with GPS in solid cancer patients.

AIM: The aim of this study is to determine the correlation between IL-6 and ferritin levels with the GPS in solid cancer patients.

METHODS: This study was an analytical observational study with a cross-sectional study approach to examine the relationship between IL-6 and ferritin levels with GPS in solid cancer patients. The sampling method was carried out by consecutive sampling. The total number of samples used in the study was 32 solid cancer subjects who had just been diagnosed. IL-6 was examined by kit enzyme-linked immunosorbent assay and ferritin using immunochemiluminescent method at certified laboratory in Manado city, Indonesia. The GPS is based on the results of the patient’s C-reactive protein and albumin levels were also examined at certified laboratory in Manado city, Indonesia. Data analysis was done using SPSS version 22.

RESULTS: There were 32 patients with solid cancer who are newly diagnosed and have not undergone chemotherapy. Out of 32 patients, 17 are men (53.13%) and 15 are women (46.87%). The median age of the subject was 52.5 (33–69) years. There was a significant relationship between IL-6 levels and GPS (p = 0.011; OR 16.67 95% CI 1.617–171.783). There was no significant relationship between ferritin levels and GPS (p = 0.148; OR 5.429 95% CI 0.807–36.506). There was a statistically significant relationship between IL-6 levels and ferritin (r = 0.554; p = 0.001).

CONCLUSION: There was a significant correlation between IL-6 and GPS and there was a significant correlation between IL-6 and ferritin in solid cancer patients. IL-6 levels can be used to assess the risk of prognosis in solid cancer patients and help provide an idea of what kind of treatment will be given to patients, and can help to determine the plan treatment at the end of the life of cancer patients.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Hanahan D. Rethinking the war on cancer. Lancet. 2014;383(9916):558-63. https://doi.org/10.1016/S0140-6736(13)62226-6 PMid:24351321 DOI: https://doi.org/10.1016/S0140-6736(13)62226-6

International Agency for Research on Cancer (IARC). Global Observatory Cancer (GLOBOCAN) 2020: Cancer for Today. Vol. 419. Lyon: International Agency for Research on Cancer; 2020. p. 1-2. Available from: https://www.gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet [Last accessed on 2021 Feb 26].

Health Research and Development Agency, Ministry of Health, Republic of Indonesia. RISKESDAS 2018 National Report. New Delhi: Balitbangkes Publishing Agency; 2019. p. 118. Available from: https://www.labdata.litbang.kemkes.go.id [Last accessed on 2021 Feb 26].

Simmons C, McMillan D, McWilliams K, Sande T, Fearon K, Tuck S, et al. Prognostic tools in patients with advanced cancer: A systematic review. J Pain Symptom Manag. 2017;53(5):962-70. https://doi.org/10.1016/j.jpainsymman.2016.12.330 PMid:28062344 DOI: https://doi.org/10.1016/j.jpainsymman.2016.12.330

Forest LM, McMillan DC, McArdle CS, Angerson W, Dunlop D. Evaluation of cumulative prognostic score based on the systemic inflammatory response in patients with inoperable non-small cell lung cancer. Br J Cancer. 2003;89(6):1028-30. https://doi.org/10.1038/sj.bjc.6601757 PMid:12966420 DOI: https://doi.org/10.1038/sj.bjc.6601242

Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, et al. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer. 2007;120(12):2600-8. https://doi.org/10.1002/ijc.22599 PMid:17304514 DOI: https://doi.org/10.1002/ijc.22599

Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces surviving gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006;12(1):11-9. https://doi.org/10.1158/1078-0432.CCR-04-1752 PMid:16397018 DOI: https://doi.org/10.1158/1078-0432.CCR-04-1752

Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38(7):904-10. https://doi.org/10.1016/j.ctrv.2012.04.007 PMid:22651903 DOI: https://doi.org/10.1016/j.ctrv.2012.04.007

Alkhateeb AA, Connor JR. The significance of ferritin in cancer: Anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 2013;1836:245-54. https://doi.org/10.1016/j.bbcan.2013.07.002 PMid:23891969 DOI: https://doi.org/10.1016/j.bbcan.2013.07.002

Lippitz B, Harris R. Cytokines patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. Oncoimunology. 2016;5(5):e1093722. https://doi.org/10.1080/2162402X.2015.1093722 PMid:27467926 DOI: https://doi.org/10.1080/2162402X.2015.1093722

Song A, Eo W, Kim S, Shim B, Lee S. Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treat with Korean medicine: A retrospective cohort study. BMC Complement Altern Med. 2018;18(1):176. https://doi.org/10.1186/s12906-018-2240-7 PMid:29879960 DOI: https://doi.org/10.1186/s12906-018-2240-7

World Health Organization. WHO Guideline on Use Ferritin Concentrations to Assess Iron Status in Individuals and Populations. Geneva: World Health Organization; 2020. p. 1-62. Available from: https://www.who.int/publications/i/item/9789240000124 [Last accessed on 2022 Mar 23].

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates incidence and mortality worldwide for 26 cancers in 185 countries. Ca Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660 PMid:33538338 DOI: https://doi.org/10.3322/caac.21660

National Cancer Institute. Age and Cancer Risk. Maryland: National Cancer Institute; 2021. p. 1-2. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/age [Last accessed on 2022 Apr 02].

Siagian D, Soeroso N, Sinaga B, Eyanoer P. Differences in serum levels of interleukin-6 in lung cancer patients and healthy people in Medan. Indones J Resporol. 2021;41(1):28-32. https://doi.org/10.36497/jri.v41i1.155 DOI: https://doi.org/10.36497/jri.v41i1.155

Kinoshita T, Ito H, Miki C. Serum Interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Am Cancer Soc. 1999;85(12):2526-31. https://doi.org/10.1002/(SICI)1097-0142(19990615)85:12%3C2526:AID-CNCR6%3E3.0.CO;2-3 PMid:10375098 DOI: https://doi.org/10.1002/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3

Vinocha A, Grover R, Deepak R. Clinical significance of interleukin-6 in diagnosis of lung, oral, esophagus and gall bladder carcinomas. J Cancer Res Ther. 2018;14:S758-60. https://doi.org/10.4103/0973-1482.183217 PMid:30249899 DOI: https://doi.org/10.4103/0973-1482.183217

Skoko M, Lasan I, Culej J, Karas G, Vucemilo T, Sturm D. Serum ferritin concentration in solid tumor patients. Libri Oncologici. 2012;40(1):1-5.

Park J, Mau C, Chen Y, SU Yen, Chen H, Huang S, et al. A case-control study in Taiwanese cohort and meta-analysis of serum ferritin in pancreatic cancer. Nature Portfolio. 202;11(1):21242. https://doi.org/10.1038/s41598-021-00650-7 PMid:34711879 DOI: https://doi.org/10.1038/s41598-021-00650-7

Gao Y, Huang D. The value of the systematic inflammation-based Glasgow prognostic score in patients with gastric cancer: A literature review. 2014;10(4):799-804. https://doi.org/10.4103/0973-1482.146054 PMid:25579511 DOI: https://doi.org/10.4103/0973-1482.146054

Brown D, Milroy R, Preston T, McMillan D. The relationship between an inflammation-based prognostic score (Glasgow prognostic score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol. 2007;60(6):705-8. https://doi.org/10.1136/jcp.2005.033217 PMid:16644880 DOI: https://doi.org/10.1136/jcp.2005.033217

Zhu L, Chen S, Ma S, Zhang S. Glasgow prognostic score predicts prognosis of non-small cell lung cancer: A meta-analysis. Springer Plus. 2016;5(1):439. https://doi.org/10.1186/s40064-016-2093-9 PMid:27104127 DOI: https://doi.org/10.1186/s40064-016-2093-9

Zhou Y, Cheng S, Fathy AH, Qian H, Zhao Y. Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: A comprehensive meta-analysis of 17 cohort studies. Onco Ther. 2018;11:1899-908. https://doi.org/10.2147%2FOTT.S154162 PMid:29670365 DOI: https://doi.org/10.2147/OTT.S154162

Zhang CX, Wang SY, Chen SQ, Yang SL, Wan L, Xiong B. Association between pretreatment Glasgow prognostic score and gastric cancer survival and clinicopathological features: A meta-analysis. Onco Ther. 2016;9:3883-91. https://doi.org/10.2147%2FOTT.S103996 PMid:27390529 DOI: https://doi.org/10.2147/OTT.S103996

Nakamura T, Katagiri H, Shido Y, Hamada S, Yamada K, Nagano A, et al. Analysis of factors for predicting survival in soft-tissue sarcoma with metastatic disease at initial presentation. Anticancer Res. 2017;37(6):3137-41. https://doi.org/10.21873/anticanres.11671 PMid:28551655 DOI: https://doi.org/10.21873/anticanres.11671

Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol. 2016;37(9):11553-72. https://doi.org/10.1007/s13277-016-5098-7 PMid:27260630 DOI: https://doi.org/10.1007/s13277-016-5098-7

Korpacka MK, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Wojcicka I, et al. Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med. 2008;46(3):359-64. https://doi.org/10.1515/CCLM.2008.089 PMid:18303990 DOI: https://doi.org/10.1515/CCLM.2008.089

Yu Y, Fan C, Tseng W, Chan P, Kuo H, Pan Y, et al. Correlation between the Glasgow prognostic score and the serum cytokine profile in Taiwanese patients with colorectal cancer. Int J Biol Markers. 2021;36(2):40-9. https://doi.org/10.1177%2F17246008211022769 PMid:34096371 DOI: https://doi.org/10.1177/17246008211022769

Lee S, Song A, Eo W. Serum ferritin as a prognostic biomarker for survival in relapsed or refractory metastatic colorectal cancer. J Cancer. 2016;7(8):957-64. https://doi.org/10.7150%2Fjca.14797 PMid:27313786 DOI: https://doi.org/10.7150/jca.14797

Giessen C, Nagel D, Glas M, Spelsberg F, Lau U, Modest D, et al. Preoperative serum markers for individual patient prognosis in stage I-III colon cancer. Tumor Biol. 2015;36(10):7897-906. https://doi.org/10.1007/s13277-015-3522-z PMid:25953265 DOI: https://doi.org/10.1007/s13277-015-3522-z

Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, et al. Pathogenesis and treatment options of cancer related anemia: Perspective for a targeted mechanism-based approach. Front Physiol. 2018;9:1294. https://doi.org/10.3389/fphys.2018.01294 PMid:30294279 DOI: https://doi.org/10.3389/fphys.2018.01294

Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, et al. Anemia in Hodgkin’s lymphoma: The role of interleukin-6 and hepcidin. J Clin Oncol. 2010;28(15):2538-43. https://doi.org/10.1200/JCO.2009.27.6873 PMid:20406921 DOI: https://doi.org/10.1200/JCO.2009.27.6873

Bao C, Zhou D, Zhu L, Qian W, Ye X. Increased serum level of interleukin-6 correlates with negative prognostic factors in extranodal NK/T-cell lymphoma. Transl Cancer Res. 2020;9(4):2378-89. https://doi.org/10.21037%2Ftcr.2020.03.49 PMid:35117598 DOI: https://doi.org/10.21037/tcr.2020.03.49